Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?

Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2022-02, Vol.145 (6), p.413-415
Hauptverfasser: Messerli, Franz H., Bavishi, Chirag, Bangalore, Sripal
Format: Artikel
Sprache:eng
Schlagworte:
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Humans
Myocardial Infarction
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 415
container_issue 6
container_start_page 413
container_title Circulation (New York, N.Y.)
container_volume 145
creator Messerli, Franz H.
Bavishi, Chirag
Bangalore, Sripal
description
doi_str_mv 10.1161/CIRCULATIONAHA.121.057835
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626891090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626891090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4131-11b65e79d9bd7c46c333e5d93bccbd9ee0ffc4701aa7fe20ab33130af34d8a13</originalsourceid><addsrcrecordid>eNpVkN9r2zAQgMXYWNNu_8Lw3vbi7E5n2dHTMKZdA2EdbUYfhSyfG2-O3UlOS_bXVyFdoXBw3PHdDz4hPiPMEXP8Wi2vq1-rcr28-lFelnOUOAdVLEi9ETNUMkszRfqtmAGATguS8kSchvA7ljkV6r04IYUEoNRMXNxu9knpObnl5Gbq-j756Tk439XdcJeUw103TjyEbkircXhgPx3a58O__ZaT5bCJ2DT68O2DeNfaPvDH53wm1hfn6-oyXV19X1blKnUZEqaIda640I2um8JluSMiVo2m2rm60czQti4rAK0tWpZga6L4qW0paxYW6Ux8Oa699-PfHYfJbLvguO_twOMuGJnLfKERNERUH1HnxxA8t-bed1vr9wbBHCya1xZNtGiOFuPsp-czu3rLzcvkf20RyI7A49hP7MOffvfI3mzY9tPGRM9AgEUqQcaABaSHFtIT9Kl_Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626891090</pqid></control><display><type>article</type><title>Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>American Heart Association</source><source>Journals@Ovid Complete</source><creator>Messerli, Franz H. ; Bavishi, Chirag ; Bangalore, Sripal</creator><creatorcontrib>Messerli, Franz H. ; Bavishi, Chirag ; Bangalore, Sripal</creatorcontrib><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.121.057835</identifier><identifier>PMID: 35130055</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Humans ; Myocardial Infarction</subject><ispartof>Circulation (New York, N.Y.), 2022-02, Vol.145 (6), p.413-415</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4131-11b65e79d9bd7c46c333e5d93bccbd9ee0ffc4701aa7fe20ab33130af34d8a13</citedby><cites>FETCH-LOGICAL-c4131-11b65e79d9bd7c46c333e5d93bccbd9ee0ffc4701aa7fe20ab33130af34d8a13</cites><orcidid>0000-0001-9485-0652 ; 0000-0002-4107-2583</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35130055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Messerli, Franz H.</creatorcontrib><creatorcontrib>Bavishi, Chirag</creatorcontrib><creatorcontrib>Bangalore, Sripal</creatorcontrib><title>Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><subject>Angiotensin Receptor Antagonists</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Humans</subject><subject>Myocardial Infarction</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkN9r2zAQgMXYWNNu_8Lw3vbi7E5n2dHTMKZdA2EdbUYfhSyfG2-O3UlOS_bXVyFdoXBw3PHdDz4hPiPMEXP8Wi2vq1-rcr28-lFelnOUOAdVLEi9ETNUMkszRfqtmAGATguS8kSchvA7ljkV6r04IYUEoNRMXNxu9knpObnl5Gbq-j756Tk439XdcJeUw103TjyEbkircXhgPx3a58O__ZaT5bCJ2DT68O2DeNfaPvDH53wm1hfn6-oyXV19X1blKnUZEqaIda640I2um8JluSMiVo2m2rm60czQti4rAK0tWpZga6L4qW0paxYW6Ux8Oa699-PfHYfJbLvguO_twOMuGJnLfKERNERUH1HnxxA8t-bed1vr9wbBHCya1xZNtGiOFuPsp-czu3rLzcvkf20RyI7A49hP7MOffvfI3mzY9tPGRM9AgEUqQcaABaSHFtIT9Kl_Dw</recordid><startdate>20220208</startdate><enddate>20220208</enddate><creator>Messerli, Franz H.</creator><creator>Bavishi, Chirag</creator><creator>Bangalore, Sripal</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9485-0652</orcidid><orcidid>https://orcid.org/0000-0002-4107-2583</orcidid></search><sort><creationdate>20220208</creationdate><title>Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?</title><author>Messerli, Franz H. ; Bavishi, Chirag ; Bangalore, Sripal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4131-11b65e79d9bd7c46c333e5d93bccbd9ee0ffc4701aa7fe20ab33130af34d8a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiotensin Receptor Antagonists</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Humans</topic><topic>Myocardial Infarction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Messerli, Franz H.</creatorcontrib><creatorcontrib>Bavishi, Chirag</creatorcontrib><creatorcontrib>Bangalore, Sripal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Messerli, Franz H.</au><au>Bavishi, Chirag</au><au>Bangalore, Sripal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2022-02-08</date><risdate>2022</risdate><volume>145</volume><issue>6</issue><spage>413</spage><epage>415</epage><pages>413-415</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>35130055</pmid><doi>10.1161/CIRCULATIONAHA.121.057835</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-9485-0652</orcidid><orcidid>https://orcid.org/0000-0002-4107-2583</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2022-02, Vol.145 (6), p.413-415
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_2626891090
source MEDLINE; EZB Electronic Journals Library; American Heart Association; Journals@Ovid Complete
subjects Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Humans
Myocardial Infarction
title Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A08%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Why%20Are%20We%20Still%20Prescribing%20Angiotensin-Converting%20Enzyme%20Inhibitors?&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Messerli,%20Franz%20H.&rft.date=2022-02-08&rft.volume=145&rft.issue=6&rft.spage=413&rft.epage=415&rft.pages=413-415&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.121.057835&rft_dat=%3Cproquest_cross%3E2626891090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2626891090&rft_id=info:pmid/35130055&rfr_iscdi=true